Xilio Therapeutics, Inc. XLO

Company Overview

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies designed to improve the therapeutic index of cancer treatments. The company operates within the oncology and immuno-oncology sectors, with research centered on selectively activating biologic therapies within the tumor microenvironment while limiting systemic toxicity. Its primary programs include masked or conditionally activated antibodies and cytokine-based therapies intended to enhance anti-tumor immune responses in solid tumors.

The company’s core business model is based on advancing proprietary immunotherapy candidates through clinical development and, where appropriate, strategic collaborations. Xilio’s platform technology is designed to enable tumor-selective activation of therapeutics using protease activity associated with tumors. The company was founded in 2020 and is headquartered in Waltham, Massachusetts. Since its formation, Xilio has focused on building a differentiated immuno-oncology pipeline targeting checkpoint pathways and cytokine signaling mechanisms that have historically faced safety limitations in systemic administration.